Deena Beasley

4 days ago | reuters.com | Deena Beasley

An Amgen sign is seen at the company's headquarters in Thousand Oaks, California, U.S., November 6, 2019. REUTERS/Deena Beasley/File Photo June 23 (Reuters) - People started on a low dose of Amgen's long-acting experimental obesity drug MariTide lost as much weight as those given high doses but with milder side effects, according to full results of a mid-stage trial presented at a medical meeting on Monday.

5 days ago | pharma.economictimes.indiatimes.com | Deena Beasley

London: Novo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23 per cent weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight.

1 week ago | pharma.economictimes.indiatimes.com | Deena Beasley |Julie Steenhuysen

Los Angeles: The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents at high risk of contracting the deadly virus. Investors and AIDS activists had been eagerly awaiting the regulatory decision for the drug seen as convenient enough to help end the 44-year-old HIV epidemic. It will be sold under the brand name Yeztugo in the U.S. at a list price of $28,218 a year.

1 week ago | theglobeandmail.com | Deena Beasley |Julie Steenhuysen

1 week ago | reuters.com | Deena Beasley |Julie Steenhuysen

Gilead Sciences pharmaceutical company is seen in Oceanside, California, U.S., April 29, 2020. REUTERS/Mike Blake/File Photo June 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' (GILD.O), opens new tab lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents. Gilead said the drug will be sold under the brand name Yeztugo. Sign up here.